GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Operating Margin %

Nutra Pharma (Nutra Pharma) Operating Margin % : -236.70% (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Nutra Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Nutra Pharma's Operating Income for the three months ended in Sep. 2022 was $-0.26 Mil. Nutra Pharma's Revenue for the three months ended in Sep. 2022 was $0.11 Mil. Therefore, Nutra Pharma's Operating Margin % for the quarter that ended in Sep. 2022 was -236.70%.

The historical rank and industry rank for Nutra Pharma's Operating Margin % or its related term are showing as below:


NPHC's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.08
* Ranked among companies with meaningful Operating Margin % only.

Nutra Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Nutra Pharma's Operating Income for the three months ended in Sep. 2022 was $-0.26 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.35 Mil.


Nutra Pharma Operating Margin % Historical Data

The historical data trend for Nutra Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma Operating Margin % Chart

Nutra Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,142.15 -1,048.09 -1,123.08 -2,088.46 -1,959.18

Nutra Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,878.95 -1,792.31 -1,400.00 -354.44 -236.70

Competitive Comparison of Nutra Pharma's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutra Pharma's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Nutra Pharma's Operating Margin % falls into.



Nutra Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nutra Pharma's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-1.92 / 0.098
=-1,959.18 %

Nutra Pharma's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-0.258 / 0.109
=-236.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutra Pharma  (OTCPK:NPHC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nutra Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutra Pharma (Nutra Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1537 NW 65th Avenue, Plantation, FL, USA, 33313
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Executives
Rik J Deitsch officer: Chief Executive Officer 4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran director 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori other: Former CFO 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph director, officer: President - ReceptoPharm 1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman officer: Chief Marketing Officer 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck director 10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid director 9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty director, officer: Executive Chairman
Tanvir A Khandaker director 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky director 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein director 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax director, officer: Chief Financial Officer 2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr director P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder director PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md director 436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired 04-19-2018